Omnicell (NASDAQ:OMCL – Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Thursday, August 1st. Analysts expect the company to announce earnings of $0.16 per share for the quarter. Omnicell has set its Q2 guidance at $0.10-0.20 EPS and its FY24 guidance at $0.90-1.40 EPS.Parties that wish to register for the company’s conference call can do so using this link.
Omnicell (NASDAQ:OMCL – Get Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.17. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. The firm had revenue of $246.15 million during the quarter, compared to the consensus estimate of $235.70 million. On average, analysts expect Omnicell to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Omnicell Price Performance
OMCL stock opened at $29.39 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.13 and a current ratio of 2.38. The stock’s 50 day moving average price is $28.62 and its 200 day moving average price is $28.99. The firm has a market cap of $1.35 billion, a P/E ratio of -63.89, a PEG ratio of 83.15 and a beta of 0.80. Omnicell has a 1 year low of $25.12 and a 1 year high of $66.65.
Analysts Set New Price Targets
Check Out Our Latest Stock Report on Omnicell
Omnicell Company Profile
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Read More
- Five stocks we like better than Omnicell
- What Investors Need to Know to Beat the Market
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- What is the Hang Seng index?
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- The How and Why of Investing in Gold Stocks
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.